Clinical trials: Reduced Ejection Fraction Heart Failure
Chronic Heart Failure With Reduced Ejection Fraction, Worsening Heart Failure
A Study to Learn How Well the Drug Vericiguat Works and How Safe it is Under Real World Conditions in Indian Participants After Worsening of a Long-term Heart Condition in Which the Left Side of the Heart Does Not Pump Blood as Well as it Should (Chronic Heart Failure With Reduced Ejection Fraction)
Researchers are looking for a better way to treat people who have chronic heart failure with reduced ejection fraction (HFrEF). HFrEF is a long-term condition where the left side of the heart does not pump blood out to the body…
- Trial name
- NCT05658458
- Testing
- Vericiguat (Verquvo, BAY1021189)
- Where
- 12 sites in India
- Volunteers
- 205 people
- Sponsor
- Bayer
Heart Failure
Study to Evaluate the Effects of AZD3427 in Patients With Heart Failure
The primary purpose of this mechanistic study is to evaluate the vasodilatory effects of AZD3427 in adult patients with heart failure and will be performed at approximately 2 study sites in the United Kingdom.
- Trial name
- NCT04890548
- Testing
- AZD3427
- Sponsor
- AstraZeneca
Heart Failure
REGN5381 in Heart Failure Adult Participants With Elevated Pulmonary Capillary Wedge Pressure
This study is researching an experimental drug called REGN5381, further referred to as study drug. The study is focused on adult participants with heart failure that, in the opinion of the study doctor, have a clinical indication…
- Trial name
- NCT05353166
- Testing
- REGN5381
- Where
- Moldova
- Volunteers
- 59 people
- Sponsor
- Regeneron Pharmaceuticals
Heart Failure, Heart Failure, Congestive
ANTHEM-HFrEF Pivotal Study
A multi-center randomized controlled clinical trial to evaluate Autonomic Regulation Therapy with the VITARIA system in patients with symptomatic heart failure and reduced ejection fraction.
- Conditions
- Heart Failure, Heart Failure, Congestive, Heart Failure, Systolic
- Trial name
- NCT03425422
- Testing
- VITARIA System
- Where
- 22 sites in United States
- Volunteers
- 533 people
- Sponsor
- LivaNova
Hypertension, Pulmonary, Heart Failure With Reduced Ejection Fraction
Deep Learning Detection of Pulmonary Hypertension and Low Ejection Fraction Via Digital Stethoscope and 3-Lead ECG
This is a prospective, observational study evaluating whether heart sounds (phonocardiograms) and three-lead electrocardiograms (ECGs) recorded using the Eko CORE 500 digital stethoscope can help detect pulmonary hypertension…
- Trial name
- PH ELEFT 2-0 (NCT07087613)
- Testing
- Eko CORE 500 Digital Stethoscope
- Where
- 4 sites in United States
- Volunteers
- 3,850 people
- Sponsor
- Eko Devices, Inc.
Heart Failure With Reduced Ejection Fraction (HFrEF), Renal Impairment
AZD3427 Effects on Renal Perfusion in Heart Failure Patients With Reduced Ejection Fraction and Renal Impairment
The present study is designed to test the effect of AZD3427 on renal perfusion in participants with heart failure and reduced eGFR (30 to 90 mL/min/1.73m2).
- Trial name
- Re-PERFUSE (NCT06611423)
- Testing
- AZD3427, Dopamine, Radiolabelled ligand
- Where
- Sweden
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Heart Diseases, Cardiovascular Diseases
Real-world Study on Dapagliflozin Usage in Patients With Heart Failure (HF) in Germany
Heart failure (HF) is a global, public health issue that affects more than 63 million people worldwide; this burden is expected to increase substantially as the population ages.
- Conditions
- Heart Diseases, Cardiovascular Diseases, Heart Failure
- Trial name
- EvolutionHF-DE (NCT06336330)
- Where
- 47 sites in Germany
- Volunteers
- 831 people
- Sponsor
- AstraZeneca
Heart Failure With Reduced Ejection Fraction, Dilated Cardiomyopathy
v4 Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491
The purpose of this Phase 1b/2a study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MYK-491 in patients with stable heart failure.
- Trial name
- NCT03447990
- Testing
- MYK-491
- Where
- 17 sites in United States, France and 5 more
- Volunteers
- 52 people
- Sponsor
- Bristol-Myers Squibb
End Stage Cardiac Failure, HFrEF - Heart Failure With Reduced Ejection Fraction
ALP-1 Continuous Intravenous Infusion to Maintain Clinical Stability in Advanced Heart Failure
This is a global multicenter, doubleblind, placebo-controlled, randomized, parallel-group study that compares ALP-1 given in a continuous infusion ( compared to placebo), 250mcg/day on majore outcomes up to 6 months after…
- Conditions
- End Stage Cardiac Failure, HFrEF - Heart Failure With Reduced Ejection Fraction, NYHF Class III-IV
- Trial name
- NCT00610051
- Testing
- Alprostadil
- Where
- Austria
- Volunteers
- 600 people
- Sponsor
- Biopeutics Co., Ltd
Chronic Heart Failure With Reduced Ejection Fraction
Efficacy and Safety of QiShen YiQi Dripping Pills in Chronic Heart Failure
This study will evaluate the efficacy and safety and the best effective dose of QiShen YiQi Dripping Pills in the treatment of chronic heart failure with decreased ejection fraction of CHD (Qi deficiency and blood stasis…
- Trial name
- NCT04983043
- Testing
- Low dose QiShen YiQi Dripping Pills 3 bags, High dose QiShen YiQi Dripping Pills 3 bags
- Where
- 23 sites in China
- Volunteers
- 228 people
- Sponsor
- Tasly Pharmaceutical Group Co., Ltd
Heart Failure, Chronic Heart Failure With Reduced Ejection Fraction
A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)
This is a randomized, placebo-controlled, parallel-group, multi-center, double-blind, event driven study of vericiguat (MK-1242) in participants with heart failure with reduced ejection fraction (HFrEF).
- Trial name
- VICTORIA (NCT02861534)
- Testing
- Vericiguat
- Volunteers
- 5,050 people
- Sponsor
- Merck Sharp & Dohme LLC
Heart Failure With Reduced Ejection Fraction
Safety and Tolerability of Initiating LCZ696 in Heart Failure Patients
The purpose of this study is to assess the safety and tolerability of initiating LCZ696 in heart failure patients with reduced ejection fraction (HF-rEF) using conservative (reaching target dose over 6 weeks) and condensed…
- Trial name
- TITRATION (NCT01922089)
- Testing
- LCZ696
- Where
- 105 sites in United States, Bulgaria and 9 more
- Volunteers
- 498 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure
Phase IIb Safety and Efficacy Study of Four Dose Regimens of BAY1021189 in Patients With Heart Failure With Reduced Ejection Fraction Suffering From Worsening Chronic Heart Failure (SOCRATES-REDUCED)
Objective of the study is to find the optimal dose of the once daily oral soluble guanylate cyclase stimulator (sGC) BAY1021189 for Phase III that can be given in addition to standard therapy for heart failure with reduced…
- Trial name
- NCT01951625
- Testing
- Vericiguat (BAY1021189) (1.25 mg), Vericiguat (BAY1021189) (5 mg)
- Where
- 157 sites in United States, Australia and 22 more
- Volunteers
- 456 people
- Sponsor
- Bayer
Cardiopulmonary Failure, Myocardial Infarction (MI)
COR-INSIGHT: Optimizing Cardiovascular and Cardiopulmonary Outcomes with AI-Driven Multiplexed Indications Using COR ECG Wearable
The COR-INSIGHT trial aims to evaluate the effectiveness of Peerbridge COR advanced ambulatory ECG wearables (COR 1.0 and COR 2.0) in accurately and non-invasively detecting cardiovascular and cardiopulmonary conditions using…
- Conditions
- Cardiopulmonary Failure, Myocardial Infarction (MI), Heart Decompensation, Heart Failure
- Trial name
- COR-INSIGHT (NCT06763549)
- Testing
- SUBPROTOCOL A, SUBPROTOCOL B, SUBPROTOCOL C
- Where
- United States
- Volunteers
- 15,000 people, healthy volunteers welcome
- Sponsor
- Peerbridge Health, Inc
Heart Failure With Reduced Ejection Fraction
Study of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF)
This is a Phase 1, randomized, double-blind, placebo-controlled, single-ascending dose study to assess the safety, tolerability, immunogenicity, PK, and exploratory efficacy of JK07 in subjects 18 to 80 years of age with HFrEF…
- Trial name
- NCT04210375
- Testing
- JK07
- Where
- 7 sites in United States
- Volunteers
- 14 people
- Sponsor
- Salubris Biotherapeutics Inc
Heart Failure
PAtient RegisTry Assessing Effectiveness and Safety of HEart Failure treatmeNt With LCZ696 acrOss CaNada
The purpose of the study is to describe the heart failure with reduced ejection fraction (HFrEF) patient population receiving sacubitril/valsartan treatment.
- Trial name
- PARTHENON (NCT02957409)
- Testing
- sacubitril/valsartan
- Where
- 32 sites in Canada
- Volunteers
- 1,009 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Reduced Ejection Fraction
Study on the Effects of Sacubitril/Valsartan on Physical Activity and Sleep in Heart Failure With Reduced Ejection Fraction Patients.
The purpose of this study was to investigate the effects of initiation of sacubitril/valsartan vs enalapril treatment on objective measures of both waking activity and sleep in subjects with heart failure with reduced ejection…
- Trial name
- AWAKE-HF (NCT02970669)
- Testing
- sacubitril/valsartan (LCZ696), enalapril
- Where
- 23 sites in United States
- Volunteers
- 140 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Cardiogenic Shock
INitiation and Titration of Guideline Directed Medical TheRApy in HearT Failure Cardiogenic Shock With ImpElla 5.5 for Cardiac Recovery
The study will evaluate the impact of a combined device-drug strategy with Impella 5.5 with best practices and optimized GDMT on heart recovery outcomes in patients with decompensated heart failure and cardiogenic shock.
- Conditions
- Heart Failure, Cardiogenic Shock, Reduced Ejection Fraction Heart Failure
- Trial name
- INTeGRATE (NCT06965504)
- Testing
- Impella 5.5 SmartAssist
- Where
- 17 sites in United States
- Volunteers
- 250 people
- Sponsor
- Abiomed Inc.
Heart Failure
ALLEVIATE-HFrEF Study
Patients with heart failure and reduced left ventricular ejection fraction (HFrEF, EF ≤ 40%) with mild to moderate functional limitation will be evaluated for treatment via creation of a no-implant interatrial shunt using…
- Trial name
- NCT05133089
- Testing
- ALV1 System
- Where
- Georgia
- Volunteers
- 5 people
- Sponsor
- Alleviant Medical, Inc.
Heart Failure With Reduced Ejection Fraction
Study to Assess the Effect of Omecamtiv Mecarbil on Exercise Capacity in Subjects With Heart Failure
The purpose of this study is to evaluate the effect of treatment with omecamtiv mecarbil compared with placebo on exercise capacity as determined by cardiopulmonary exercise testing following 20 weeks of treatment with omecamtiv…
- Trial name
- METEORIC-HF (NCT03759392)
- Testing
- Omecamtiv Mecarbil
- Where
- 81 sites in United States, Canada and 7 more
- Volunteers
- 276 people
- Sponsor
- Cytokinetics